在经济结构转型与健康需求升级的双重背景下,医疗健康产业始终是资本市场的核心关注领域。有机构近日研报指出,2026年医药行业内外因催化因素将持续发力,行业正回归临床价值导向的发展正轨,有望维持超配地位。创新成果的集中兑现,构成了医药行业增长的核心内生动力。经过多年研发投入与技术积累,中国医药企业已从仿制药为主的阶段,迈入创新药械密集产出期。从PD-1抑制剂等肿瘤治疗药物的适应症拓展,到微创介入器械、...
Source Link在经济结构转型与健康需求升级的双重背景下,医疗健康产业始终是资本市场的核心关注领域。有机构近日研报指出,2026年医药行业内外因催化因素将持续发力,行业正回归临床价值导向的发展正轨,有望维持超配地位。创新成果的集中兑现,构成了医药行业增长的核心内生动力。经过多年研发投入与技术积累,中国医药企业已从仿制药为主的阶段,迈入创新药械密集产出期。从PD-1抑制剂等肿瘤治疗药物的适应症拓展,到微创介入器械、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.